每經AI快訊，*ST目(mu)藥（SH 600671，收盤價：9.98元）8月20日(ri)晚間發布(bu)公(gong)(gong)(gong)告稱，協議自雙方簽(qian)署之(zhi)日(ri)起生效(xiao)，期限兩年，永新(xin)華(hua)瑞(rui)持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)2500萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)、占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)的(de)20.53%，應(ying)(ying)急共(gong)(gong)享(xiang)持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)400萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)、占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)的(de)3.28%，雙方簽(qian)署一致(zhi)行動(dong)人協議后，合計持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)2900萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)、占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)的(de)23.81%，成為(wei)公(gong)(gong)(gong)司(si)(si)(si)第(di)一大(da)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)東(dong)。本(ben)次權益變(bian)動(dong)后，永新(xin)華(hua)瑞(rui)持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)2477萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)，占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)比例為(wei)20.34%；應(ying)(ying)急共(gong)(gong)享(xiang)持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)400萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)，占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)比例為(wei)3.28%；青(qing)島(dao)匯(hui)(hui)隆華(hua)澤投(tou)資有(you)限公(gong)(gong)(gong)司(si)(si)(si)持(chi)有(you)公(gong)(gong)(gong)司(si)(si)(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份(fen)(fen)(fen)約(yue)(yue)2680萬(wan)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)、占公(gong)(gong)(gong)司(si)(si)(si)總(zong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)比例為(wei)22.01%，公(gong)(gong)(gong)司(si)(si)(si)第(di)一大(da)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)東(dong)由永新(xin)華(hua)瑞(rui)及應(ying)(ying)急共(gong)(gong)享(xiang)變(bian)更為(wei)匯(hui)(hui)隆華(hua)澤。

2022年1至12月份，*ST目藥的營業收入構成(cheng)為：藥品(pin)(pin)-流通商品(pin)(pin)占(zhan)(zhan)比(bi)(bi)(bi)36.79%，原料藥占(zhan)(zhan)比(bi)(bi)(bi)31.92%，西藥占(zhan)(zhan)比(bi)(bi)(bi)9.89%，其他(ta)行業占(zhan)(zhan)比(bi)(bi)(bi)7.57%，中成(cheng)藥占(zhan)(zhan)比(bi)(bi)(bi)7.2%，保健品(pin)(pin)業占(zhan)(zhan)比(bi)(bi)(bi)5.76%。

*ST目藥的(de)董(dong)事(shi)長是李峰，男(nan)，46歲，學歷背(bei)景為本科；總經理是劉波，男(nan)，48歲，學歷背(bei)景為碩士。

截(jie)至(zhi)發稿，*ST目(mu)藥市值為12億元。

道達號（daoda1997）“個(ge)股趨勢”提醒(xing)：
1. 近30日內無機構對*ST目藥進行調研。
更(geng)多(duo)個(ge)股趨勢信息，請(qing)搜索微(wei)信公眾號(hao)“道達號(hao)”，回復“查詢(xun)”，領取免費查詢(xun)權限！

每經頭條（nbdtoutiao）——

(記者 蔡鼎)

免(mian)責聲明：本(ben)文內容與數據(ju)(ju)僅供參考，不構成(cheng)投資建議，使用前請核實(shi)。據(ju)(ju)此操作，風險自擔。